Tackle cancers with substantial unmet need

Over the last 40 years, improvements in prevention, detection and treatment have revolutionised cancer medicine and survival has doubled. However, progress has not advanced equally for all forms of the disease.

Our ambition is to increase our investment twoto threefold over the next five years in lung, pancreatic, oesophageal cancer and brain tumours

Our approach

Our ambition is to increase our investment two- to threefold over the next five years for each of these cancers to strengthen long-term research capacity. We will make targeted investments aimed at building leadership, training and facilitating better networking. We will also work with the research community to encourage new, high-quality proposals in order to grow the share of competitive funding for these cancers over time.

We will increase focus on these cancers within our Institutes and Centres, prioritise within our existing funding streams and collaborate with other cancer-specific charities, particularly in brain and pancreatic cancer. We will prioritise them within our strategic initiatives and make specific targeted investments.

There is currently a high unmet medical need and lack of research investment in rare cancers, which make up around a fifth of all cancer diagnoses in Europe.

We will continue to support a range of clinical research into rare cancers, including the International Rare Cancers Initiative (IRCI), a joint initiative between ourselves and the National Institute for Health Research Cancer Research Network (NCRN), the US National Cancer Institute (NCI), the French National Cancer Institute (INCA) and the European Organisation for Research and Treatment of Cancer (EORTC).

Although cancer in children, teenagers and young adults is rare, it is the most common cause of death in children and the most common cause of death by disease in teenagers and young adults. We are the major funder of childhood cancer research in the UK, supporting 60% of all children’s cancer trials. With limited investment from pharmaceutical companies in this area, we have an important role to play and are committed to doing more.

We will increase investment in this area by encouraging funding through our committees and by working with the research community to address some of the key issues currently inhibiting progress. In particular, we will support research into cancers where survival is still low and research to address the long-term physical side effects of treatment and quality of life issues for survivors of children’s cancers.

Opportunities for your research

We're prioritising cancers of unmet need across our funding streams, at all stages of career development and the research pipeline and patient pathway. Our Research Funding Managers are available to discuss and help you develop your ideas.

Our progress

Share this page